Physician profile
Ajoy Roy
NPI 1487633400
$3,123.56
in general payments reported to CMS, 2019-2025
22 companies · $521 in 2025
The $521 reported for 2025 was more than what 79% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $579 · 2020: $272 · 2021: $422 · 2022: $655 · 2023: $566 · 2024: $109 · 2025: $521.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,195.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $787.95 | 2019-2023 | Skyrizi, Mavyret, Rinvoq |
| Pfizer INC. | $566.88 | 2019-2023 | |
| Gilead Sciences, INC. | $435.79 | 2019-2025 | Epclusa, Livdelzi |
| Takeda Pharmaceuticals U.S.A., INC. | $293.98 | 2019-2025 | Entyvio, Gattex |
| Janssen Biotech, INC. | $287.87 | 2019-2023 | Stelara |
| Phathom Pharmaceuticals, INC. | $154.82 | 2025 | Voquezna |
| Janssen Scientific Affairs, LLC | $113.99 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $108.59 | 2019 | |
| Intercept Pharmaceuticals, INC. | $57.65 | 2019 | |
| Celgene Corporation | $44.72 | 2021-2023 | |
| Ferring Pharmaceuticals INC. | $43.51 | 2020-2023 | Rebyota |
| Braintree Laboratories, INC. | $38.32 | 2022-2023 | Sutab |
| Genzyme Corporation | $32.76 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $28.67 | 2023 | Dupixent |
| Ipsen Biopharmaceuticals, INC | $18.45 | 2025 | Iqirvo |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $18.38 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $18.29 | 2022 | |
| Qol Medical, LLC | $17.48 | 2019 | |
| Boston Scientific Corporation | $14.78 | 2019 | |
| Alfasigma USA, INC. | $14.76 | 2020 | |
| Endo Pharmaceuticals INC. | $14.23 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.69 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ajoy Roy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.